Abstract:Background: Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of fibrotic liver disease and hepatocellular carcinoma (HCC). Dysregulated TGF-β signaling and loss of SIRT6 activity are implicated in fatty liver disease. SIRT6 limits fibrosis by inhibiting SMAD3 activity and limits de novo lipogenesis by inhibiting SREBP1 and SREBP2 activity. We hypothesized that altered reciprocal regulation between TGF-β signaling and SIRT6 contributes to NAFLD and its progression. The goal of this study was to identify regulatory crosstalk between SIRT6 and SMAD3 and SPTBN1, a regulator of SMAD3 activity. Methods: We used bioinformatics and chromatin immunoprecipitation (ChIP) with HepG2 cells to examine the binding of SMAD3 or CTCF to the SIRT6 gene in the presence or absence of TGF-β. Using cultured cells, we examined the effect of altering SPTBN1 or SMAD3 on SIRT6 abundance, and of altering SIRT6 on SPTBN1 and SMAD3 abundance. We examined liver phenotypes of SPTBN1+/- mice fed either a normal chow diet or a high-fat diet (HFD) and monitored body weight and serum total cholesterol and triglyceride concentrations, as well as analyzed liver tissue for SIRT6 abundance. Results: We identified two consensus SMAD-binding elements and two consensus CTCF binding sites in the SIRT6 promoter and showed by ChIP that TGF-β stimulated SMAD3 and CTCF binding to the promoter region of SIRT6. We found that deficiency in SMAD3 or SPTBN1 reduced SIRT6 mRNA and protein abundance. Overexpression of SIRT6 reduced expression of selected TGF-β-induced genes. Knockdown of SIRT6 increased SPTBN1 but not SMAD3 abundance and overexpression of SIRT6 reduced only SPTBN1 abundance. We found that fatty liver and associated metabolic changes induced by HFD is worse in SPTBN1+/- mice than in control mice. Furthermore, this condition was associated with reduced SIRT6 protein abundance in the liver. Conclusions: We found a reciprocal regulatory mechanism involving SPTBN1 through which SIRT6 can influence TGF-β signaling and identified SIRT6 as a target of TGF-β-SMAD3 signaling. The development of liver steatosis with reduced SIRT6 in SPTBN1+/- mice suggested that impaired induction of SIRT6 contributes to the severe liver phenotype, which resembles nonalcoholic steatohepatitis (NASH). Future investigation may yield opportunities to intervene and prevent NAFLD from progressing to NASH and thus reduce the risk of HCC. Citation Format: Kazufumi Ohshiro, Xiyan Xiang, David Bernstein, James M. Crawford, Bibhuti Mishra, Patricia S. Latham, Nancy R. Gough, Shuyun Rao, Lopa Mishra. Impaired reciprocal regulation between SIRT6 and TGF-β signaling as a potential mechanism for development and progression of fatty liver [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 1463.

Cytoplasmic SIRT6-mediated ACSL5 deacetylation impedes nonalcoholic fatty liver disease by facilitating hepatic fatty acid oxidation

Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease

Abstract 1463: Impaired reciprocal regulation between SIRT6 and TGF-β signaling as a potential mechanism for development and progression of fatty liver

[The role of SIRT6 in nonalcoholic steatohepatitis]

Elucidation of SIRT-1/PGC-1α-associated mitochondrial dysfunction and autophagy in nonalcoholic fatty liver disease

Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4α

Impaired SUMOylation of FoxA1 promotes nonalcoholic fatty liver disease through down-regulation of Sirt6

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

Sirt6 Alleviated Liver Fibrosis by Deacetylating Conserved Lysine 54 on Smad2 in Hepatic Stellate Cells

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

Allyl Isothiocyanate Ameliorates Lipid Accumulation and Inflammation in Nonalcoholic Fatty Liver Disease Via the Sirt1/AMPK and NF-κB Signaling Pathways.

Sirtuin 3‐mediated deacetylation of acyl‐ CoA synthetase family member 3 by protocatechuic acid attenuates non‐alcoholic fatty liver disease

Dysfunction of Autophagy in High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease

Impaired reciprocal regulation between SIRT6 and TGF‐β signaling in fatty liver

SIRT2 Deficiency Aggravates Diet-Induced Nonalcoholic Fatty Liver Disease through Modulating Gut Microbiota and Metabolites

Fatty Acids Promote Fatty Liver Disease Via the Dysregulation of 3-Mercaptopyruvate Sulfurtransferase/hydrogen Sulfide Pathway.

ATL I, Acts as a SIRT6 Activator to Alleviate Hepatic Steatosis in Mice via Suppression of NLRP3 Inflammasome Formation

Sirtuin 6—A Key Regulator of Hepatic Lipid Metabolism and Liver Health

Activation of TAF9 via Danshensu-Induced Upregulation of HDAC1 Expression Alleviates Non-alcoholic Fatty Liver Disease

Hepatic-Specific Disruption of Sirt6 in Mice Results in Fatty Liver Formation Due to Enhanced Glycolysis and Triglyceride Synthesis

A novel peptide encoded by circ-SLC9A6 promotes lipid dyshomeostasis through the regulation of H4K16ac-mediated CD36 transcription in NAFLD